Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 11/20 | 0.47 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.47 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.42 |
| ▸ | CCR1 | P32246 | 4/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17303216 | 1.00 | DPP4 (0.47) | DPP4DPP8DPP9ABL1BCR | |
| SCHEMBL15458238 | 1.00 | DPP4 (0.47) | DPP4DPP8DPP9ABL1BCR | |
| SCHEMBL888766 | 0.84 | CCR1 (0.41) | DPP4DPP8DPP9ABL1BCR | |
| SCHEMBL10299181 | 0.84 | CCR1 (0.41) | ABL1BCRCCR1CYP3A4KCNH2 | |
| SCHEMBL888896 | 0.84 | CCR1 (0.41) | DPP4DPP8DPP9ABL1BCR | |
| SCHEMBL15457795 | 0.84 | CCR1 (0.41) | ABL1BCRCCR1CYP3A4KCNH2 | |
| SCHEMBL17303219 | 0.84 | CCR1 (0.41) | ABL1BCRCCR1CYP3A4KCNH2 | |
| SCHEMBL15457791 | 0.84 | CCR1 (0.41) | ABL1BCRCCR1CYP3A4KCNH2 | |
| SCHEMBL15691835 | 0.83 | KDM5A (0.47) | ABL1BCRCCR1CYP3A4KCNH2 | |
| SCHEMBL12824396 | 0.82 | CCR1 (0.38) | ABL1BCRCCR1CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004196-A1 | Anti-Viral Compounds | Abbott Labaoratories (US) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004196-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | DPP4 159/4885DPP8 295/4885DPP9 483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.